We have located links that may give you full text access.
Urine Angiotensin II Signature Proteins as Markers of Fibrosis in Kidney Transplant Recipients.
Transplantation 2019 Februrary 20
BACKGROUND: Interstitial fibrosis/tubular atrophy (IFTA) is an important cause of kidney allograft loss; however, noninvasive markers to identify IFTA or guide anti-fibrotic therapy are lacking. Using angiotensin-II (AngII) as the prototypical inducer of IFTA, we previously identified 83 AngII-regulated proteins in vitro. We developed mass spectrometry-based assays for quantification of 6 AngII signature proteins (BST1, GLNA, LAMB2, LYPLA1, RHOB and TSP1) and hypothesized that their urine excretion will correlate with IFTA in kidney transplant patients.
METHODS: Urine excretion of 6 AngII regulated proteins was quantified using selected reaction monitoring (SRM) and normalized by urine creatinine. Immunohistochemistry was used to assess protein expression of TSP1 and GLNA in kidney biopsies.
RESULTS: The urine excretion rates of AngII-regulated proteins were found to be increased in 15 kidney transplant recipients with IFTA compared to 20 matched controls with no IFTA (mean log2[fmol/µmol of creatinine], BST1: 3.8 vs 3.0, p = 0.03; GLNA: 1.2 vs -0.4, p = 0.03; LAMB2: 6.1 vs 5.4, p = 0.06; LYPLA1: 2.1 vs 0.6, p = 0.002; RHOB: 1.2 vs -0.1, p = 0.006; TSP1_GGV: 2.5 vs 1.9; p = 0.15; TSP1_TIV: 2.0 vs. 0.6; p = 0.0006). ROC curve analysis demonstrated an AUC=0.86 for the ability of urine AngII signature proteins to discriminate IFTA from controls. Urine excretion of AngII signature proteins correlated strongly with chronic interstitial fibrosis/tubular atrophy and total inflammation. In a separate cohort of 19 kidney transplant recipients, the urine excretion of these 6 proteins was significantly lower following therapy with AngII inhibitors (p < 0.05).
CONCLUSIONS: AngII-regulated proteins may represent markers of IFTA and may guide anti-fibrotic therapies.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
METHODS: Urine excretion of 6 AngII regulated proteins was quantified using selected reaction monitoring (SRM) and normalized by urine creatinine. Immunohistochemistry was used to assess protein expression of TSP1 and GLNA in kidney biopsies.
RESULTS: The urine excretion rates of AngII-regulated proteins were found to be increased in 15 kidney transplant recipients with IFTA compared to 20 matched controls with no IFTA (mean log2[fmol/µmol of creatinine], BST1: 3.8 vs 3.0, p = 0.03; GLNA: 1.2 vs -0.4, p = 0.03; LAMB2: 6.1 vs 5.4, p = 0.06; LYPLA1: 2.1 vs 0.6, p = 0.002; RHOB: 1.2 vs -0.1, p = 0.006; TSP1_GGV: 2.5 vs 1.9; p = 0.15; TSP1_TIV: 2.0 vs. 0.6; p = 0.0006). ROC curve analysis demonstrated an AUC=0.86 for the ability of urine AngII signature proteins to discriminate IFTA from controls. Urine excretion of AngII signature proteins correlated strongly with chronic interstitial fibrosis/tubular atrophy and total inflammation. In a separate cohort of 19 kidney transplant recipients, the urine excretion of these 6 proteins was significantly lower following therapy with AngII inhibitors (p < 0.05).
CONCLUSIONS: AngII-regulated proteins may represent markers of IFTA and may guide anti-fibrotic therapies.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app